A 58-year-old woman from Mumbai presents with fatigue and bone pain for 4 months. Laboratory findings include hemoglobin 7.8 g/dL, serum calcium 12.2 mg/dL, serum creatinine 1.9 mg/dL, and serum albumin 2.3 g/dL. Serum protein electrophoresis shows an M-spike of 3.8 g/dL. Bone marrow biopsy reveals 28% clonal plasma cells with cytoplasmic immunoglobulin G (IgG) and kappa light chain restriction on flow cytometry. Skeletal survey shows multiple lytic lesions in the skull and pelvis. What is the most likely immunophenotype of the neoplastic plasma cells?

Explanation

## Understanding Plasma Cell Immunophenotype in Multiple Myeloma ### Normal vs. Neoplastic Plasma Cell Differentiation **Key Point:** Plasma cells are the terminal differentiation stage of B lymphocytes. During this transition, cells **lose B-cell markers** (CD19, CD45) and **gain plasma cell markers** (CD138, cytoplasmic immunoglobulin). ### Immunophenotypic Progression ```mermaid flowchart LR A[Hematopoietic Stem Cell]:::outcome --> B[Pro-B Cell]:::outcome B --> C[Pre-B Cell]:::outcome C --> D[Immature B Cell]:::outcome D --> E[Mature B Cell]:::outcome E -->|CD19+, CD45+<br/>Surface Ig+| F[Activated B Cell]:::outcome F --> G[Plasma Cell]:::outcome G -->|CD138+, CD19−, CD45−<br/>Cytoplasmic Ig+| H[Antibody Secretion]:::action ``` ### Immunophenotype of Normal Plasma Cells | Marker | Expression | Significance | | --- | --- | --- | | **CD138** | **Positive** | Pan-plasma cell marker; most specific | | **CD19** | **Negative** | Lost during plasma cell differentiation | | **CD45** | **Negative** | Lost during plasma cell differentiation | | **Surface Ig** | **Negative** | Internalized and secreted as cytoplasmic Ig | | **Cytoplasmic Ig** | **Positive** | Abundant in antibody-secreting cells | | **CD27** | Positive | Memory B cell/plasma cell marker | | **CD38** | Positive | Activation marker | | **HLA-DR** | Negative | Lost in terminal differentiation | **High-Yield:** The **CD138+, CD19−, CD45− phenotype** is the hallmark of normal and neoplastic plasma cells. ### Why Surface Ig is Lost **Clinical Pearl:** During plasma cell differentiation: 1. Surface immunoglobulin is **internalized** into the endoplasmic reticulum and Golgi apparatus. 2. Antibody is **synthesized and secreted** in large quantities (cytoplasmic accumulation). 3. Surface Ig becomes **undetectable** by flow cytometry. This is why the question specifies **"cytoplasmic immunoglobulin G (IgG) and kappa light chain restriction"** — the neoplastic plasma cells are actively secreting the M-protein. ### Abnormal Immunophenotypes in Myeloma (Clonality Markers) **Key Point:** Flow cytometry detects clonality by identifying **aberrant** (abnormal) plasma cell phenotypes: | Aberrant Feature | Significance | | --- | --- | | **CD19 expression on CD138+ cells** | Abnormal; normal plasma cells are CD19− | | **CD45 expression on CD138+ cells** | Abnormal; normal plasma cells are CD45− | | **Surface Ig on CD138+ cells** | Abnormal; normal plasma cells have cytoplasmic Ig only | | **Monotypic light chain (kappa or lambda only)** | Clonality marker; normal has kappa:lambda ≈ 2:1 | | **CD56 expression** | Aberrant in ~70% of myeloma; associated with extramedullary disease | | **CD117 expression** | Aberrant in ~30% of myeloma | **Mnemonic: "PLASMA CELLS LOSE B-CELL MARKERS"** - **P**lasma cells: CD138+ - **L**ose: CD19, CD45 - **A**cquire: Cytoplasmic Ig - **S**urface Ig: Negative - **M**onoclonal: Single light chain type - **A**berrant: CD56, CD117 (in subsets) ## Why This Answer is Correct Option 1 (CD138+, CD19−, CD45−, cytoplasmic immunoglobulin+) represents the **normal/expected immunophenotype of plasma cells**, both normal and neoplastic. The patient's bone marrow shows 28% clonal plasma cells with this phenotype, confirming multiple myeloma.